NEW YORK – Three new studies presented at the American Society of Clinical Oncology's virtual annual meeting are highlighting the potential value of Exact Sciences' Oncotype DX Breast Recurrence Score test for helping to determine whether women with hormone receptor positive, HER2-negative breast cancer can avoid the use of neoadjuvant chemotherapy.
One of the studies showed that the test could be especially beneficial in the decision-making process for younger patients in need of neoadjuvant therapy, which could lead to an expanded use of the test.